Stockscreener 앱 받기
0.9001
4.24%
-0.0399
전일 마감가:
$0.94
열려 있는:
$0.94
하루 거래량:
32,219
Relative Volume:
0.09
시가총액:
$61.93M
수익:
-
순이익/손실:
$-86.08M
주가수익비율:
-0.4172
EPS:
-2.1574
순현금흐름:
$-72.06M
1주 성능:
+0.56%
1개월 성능:
-4.46%
6개월 성능:
-31.81%
1년 성능:
-51.08%
1일 변동 폭
$0.92
$0.9837
1주일 범위
$0.8711
$1.0656
52주 변동 폭
$0.66
$1.89
Io Biotech Inc Stock (IOBT) Company Profile
명칭
Io Biotech Inc
전화
(457) 070-2980
주소
OLE MAALOES VEH 3, COPENHAGEN
IOBT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.926 | 61.93M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.94 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.11 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
662.88 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.00 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Io Biotech Inc 주식(IOBT)의 최신 뉴스
Melanoma FDA Approvals, Pipeline Insights, Clinical Trials Assessment and Companies | DelveInsight - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update - MarketBeat
Jefferies maintains IO Biotech Buy rating, $8 target on PFS hopes - MSN
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy - MSN
Non-small Cell Lung Cancer Clinical and Non-Clinical Studies, - openPR
IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short Interest - MarketBeat
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor - Healio
IO Biotech Completes Enrollment in Its Neoadjuvant/Adjuvant Phase 2 Basket Trial (IOB-032/PN-E40) - Marketscreener.com
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer - The Manila Times
IO Biotech Fast-Tracks Cancer Vaccine Trial, Completes Phase 2 Enrollment Early - StockTitan
5 Best Microbiome Companies (January 2025) - Securities.io
IO Biotech faces possible Nasdaq delisting over low stock price By Investing.com - Investing.com Nigeria
IO Biotech faces possible Nasdaq delisting over low stock price - Investing.com India
IO Biotech Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement - Defense World
IO Biotech's chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Australia
IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 210.5% in December - MarketBeat
IO Biotech’s chief medical officer acquires $26,553 in common stock By Investing.com - Investing.com Nigeria
IO Biotech's chief medical officer acquires $26,553 in common stock - Investing.com
Io biotech general counsel Devin Smith acquires $9,720 in shares By Investing.com - Investing.com Nigeria
IO Biotech CEO Mai-Britt Zocca acquires $10,120 in company stock - Investing.com India
IO Biotech (NASDAQ:IOBT) Adopts Amended and Restated Bylaws - Defense World
Io biotech general counsel Devin Smith acquires $9,720 in shares - Investing.com India
IO Biotech CFO Amy Sullivan buys $8,482 in common stock By Investing.com - Investing.com Nigeria
IO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in Stock - MarketBeat
IO Biotech CFO Amy Sullivan buys $8,482 in common stock - Investing.com
IO Biotech Secures €57.5 Million Debt Financing from European Investment Bank - Defense World
IO Biotech announces up to €57.5M debt financing from the European Investment Bank - MSN
IO Biotech Secures Up To €57.5 Million In Debt Financing From The European Investment Bank - citybiz
IO Biotech secures €57.5 million EIB loan for cancer vaccines By Investing.com - Investing.com Canada
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank - Marketscreener.com
IO Biotech Secures €57.5M EIB Loan Facility to Advance Cancer Vaccine Development Pipeline - StockTitan
IO Biotech (NASDAQ:IOBT) Trading Down 1.3%Here's Why - MarketBeat
IO Biotech (NASDAQ:IOBT) Shares Down 1.3% – Here’s What Happened - Defense World
IO Biotech amends bylaws and adjusts fiscal year-end - Investing.com
IO Biotech : Amendments to Bylaws Form 8 K - Marketscreener.com
IO Biotech amends bylaws and adjusts fiscal year-end By Investing.com - Investing.com UK
Cancer Vaccines Pipeline Drugs Analysis Report, 2024: FDA - openPR
(PDF) 756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC) - ResearchGate
Cancer Vaccines Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - Barchart
Cancer Vaccines Market Forecasted to Surge in Coming Years, - openPR
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Pipeline, Epidemiology and Companies by DelveInsight - Barchart
Head and Neck Squamous Cell Carcinoma Treatment Market 2032: - openPR
IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register
IO Biotech stock hits 52-week low at $0.73 amid market challenges - Investing.com UK
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.51% - MSN
HC Wainwright Decreases Earnings Estimates for IO Biotech - MarketBeat
Neuronetics (NASDAQ: STIM) Announces Key Financial Updates and FDA Clearance for Adolescent Treatment - Defense World
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Receives $62.50 Average Price Target from Analysts - Defense World
IO Biotech (NASDAQ:IOBT) Given "Buy" Rating at HC Wainwright - MarketBeat
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Io Biotech Inc (IOBT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):